Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-25T05:19:21.240Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine use in a patient with schizophrenia and the risk of diabetes

Published online by Cambridge University Press:  16 April 2020

V. Folnegović-Šmalc ,
V. Jukić ,
O. Kozumplik ,
N. Mimica  and
S. Uzun
V. Folnegović-Šmalc
Affiliation:
University Department of Psychiatry, Psychiatric Hospital Vrapče, Bolnička cesta 32, 10090Zagreb, Croatia
V. Jukić
Affiliation:
University Department of Psychiatry, Psychiatric Hospital Vrapče, Bolnička cesta 32, 10090Zagreb, Croatia
O. Kozumplik
Affiliation:
University Department of Psychiatry, Psychiatric Hospital Vrapče, Bolnička cesta 32, 10090Zagreb, Croatia
N. Mimica
Affiliation:
University Department of Psychiatry, Psychiatric Hospital Vrapče, Bolnička cesta 32, 10090Zagreb, Croatia
S. Uzun*
Affiliation:
University Department of Psychiatry, Psychiatric Hospital Vrapče, Bolnička cesta 32, 10090Zagreb, Croatia
*
*Corresponding author. University Department for General and Forensic Psychiatry and Clinical Neuropsychophysiology, PH Vrapče, Bolnička cesta 32, 10090 Zagreb, Croatia. E-mail address:suzana.uzun@bolnica-vrapce.hr (S. Uzun).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

SchizophreniaOlanzapineDiabetes
Type
Case report
Information
European Psychiatry , Volume 19 , Issue 1 , January 2004 , pp. 62 - 64
Copyright
Copyright © 2003 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, DBMentore, JLHeo, MChandler, LPCappelari, JCInfante, MCet al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): APA; 1994.Google Scholar
Henderson, DC. Atypical antipsychotic—induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002;16(2):77–89.10.2165/00023210-200216020-00001CrossRefGoogle ScholarPubMed
Lindenmayer, JPNathan, AMSmith, RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(23):30–8.Google ScholarPubMed
Mir, STaylor, D. Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001;16(2):63–73.CrossRefGoogle Scholar
Rigalleau, VGatta, BBonnaud, SMasson, MBourgeois, MLVergnot, Vet al. Diabetes as a result of atypical antipsychotic drugs—a report of three cases. Diabet Med 2000;17(6):484–6.10.1046/j.1464-5491.2000.00296.xCrossRefGoogle ScholarPubMed
Rockwell, WJKEllinwood, EHTrader, DW. Psychotropic drugs promoting weight gain: health risk and treatment implications. South Med J 1983;76:1407–12.10.1097/00007611-198311000-00021CrossRefGoogle Scholar
Schatzberg, AFNemeroff, CB. Textbook of psychopharmacology. Washington (DC): American Psychiatric Press; 1998.Google Scholar
Wirshing, DASpellberg, BJErhart, SMMarder, SRWirshing, WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44(8):778–83.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.